Abstract: The disclosure relates to a pharmaceutical composition having the efficacy of preventing and treating lung injury, a preparation method therefor and a use thereof. The composition comprises a grape powder with a content of 1-25% (w/w), a grape seed extract with a content of 0.5-15% (w/w) and a pharmaceutically acceptable carrier. The composition of the disclosure has the efficacy of preventing and treating lung injury, oxidative injury, inhibiting pulmonary fibrosis, regulating lipid metabolism, and the like.

Abstract: This disclosure related to a group of peptide derivative Omicsynins with antiviral activity against influenza virus and coronavirus. It also related uses of these derivatives, the chemical formula of the peptide derivative Omicsynins is shown in formula (1): R1—R4 are shown in the following table. NO. substituent1 substituent2 substituent3 R1 Basic amino-acid side chains including lysine, histidine, citrulline residues, and etc. R2 —CH(CH3)2, —CH(CH3)CH2CH3 —CH2CH(CH3)2 Neutral amino-acid side chain including tryptophan, serine, threonine, cysteine residues and etc. R3 R3 including tyrosine, lysine, histidine, citrulline residues, and etc. R4 —CH2OH —CHO R4 including —CH2NH2, —CH?NH,— CH?NOH, —COOH, —COOR5 (R5 represents alkyl groups containing 1-3 carbons), -CONH2 and etc.

Abstract: The present invention relates to a method for preventing or treating a coronavirus infectious disease, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound represented by formula (I) or pharmaceutically acceptable salts thereof. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in all of the clearance rate by viral nucleic acid test, the course of clearance, and the cure and discharge time.

Abstract: The present application relates to the use of berberine as shown in formula (I) or an active metabolite thereof and a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing and/or treating phenylketonuria.

Abstract: Provided are a new aromatic cyanogen compound and a preparation method thereof. The present invention also relates to the use of such compound in antiviral drugs, in particular the use thereof in anti-HCV drugs.

Abstract: A voltage regulator having a pre-regulator circuit is disclosed. A low dropout (LDO) voltage regulator includes an amplifier circuit, a current buffer circuit, and a pre-regulator circuit. The current buffer circuit includes a transistor having a gate terminal coupled to the amplifier output. The current buffer provides a current based at least in part on the output signal generated by the amplifier. The pre-regulator circuit is coupled to provide a dynamic supply voltage to the current buffer. They dynamic supply voltage depends at least in part on a fixed supply voltage provided thereto, as well as the output voltage provided by the LDO voltage regulator.

Abstract: Provided are a new aromatic cyanogen compound and a preparation method thereof. The present invention also relates to the use of such compound in antiviral drugs, in particular the use thereof in anti-HCV drugs.

Abstract: The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.

Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

Abstract: DC to DC converters and PWM controllers are presented in which a slope compensation ramp signal is provided for current control operation via a frequency adaptive compensation circuit with a phase locked loop that provides a control output signal having an amplitude generally proportional to the frequency of a clock signal, and a slope generator circuit generating the slope compensation ramp signal with an amplitude generally proportional to the control output signal amplitude.

Abstract: The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.

Abstract: DC to DC converters and PWM controllers are presented in which a slope compensation ramp signal is provided for current control operation via a frequency adaptive compensation circuit with a phase locked loop that provides a control output signal having an amplitude generally proportional to the frequency of a clock signal, and a slope generator circuit generating the slope compensation ramp signal with an amplitude generally proportional to the control output signal amplitude.

Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

Abstract: The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/or AIDS.

Abstract: A set of geldanamycin derivatives and their preparation methods. Pharmaceutical compositions comprising the said compounds as an active ingredient which are used as antivirus and antitumor agents. The said derivatives are used in the manufacture of heat shock protein 90 (Hsp 90) inhibiting agents which have the utility as antivirus and antitumor agents.

Abstract: A pre-charge apparatus and method for controlling startup transients in a capacitively-coupled switching power stage provide lower cost and improved startup transient performance in Class D amplifiers, as well as in other AC power converter applications. A charging source is activated at startup to control the charging of an external capacitor from a single power supply rail to an operating point voltage equal to the average DC output of the switching circuit, while a control circuit disables the output power stage of the switching converter. The current source may be a constant-current source and/or may be controlled via feedback from the voltage or current at the output terminal of the converter to taper the current level to more accurately control the charging. A discharge circuit can also be provided to discharge the output terminal to an opposite power supply rail before commencing the controlled charging.

Abstract: Disclosed are methods and apparatus for over-current detection in PWM power stages. Disclosed methods and apparatus provide over-current detection with adaptive filtering according to the pulse width of the PWM input signal. Methods and apparatus for their implementation are described for detecting the pulse width of a PWM signal in the PWM circuit. According to the detected pulse width, a digital delay less than the pulse width of the PWM signal is selected from among a plurality of available digital delays. Further, an over-current condition in the PWM power stage is detected. The detected over-current signal is filtered by means of the selected digital delay and an over-current detection result is output.

Abstract: Disclosed are methods and apparatus for over-current detection in PWM power stages. Disclosed methods and apparatus provide over-current detection with adaptive filtering according to the pulse width of the PWM input signal. Methods and apparatus for their implementation are described for detecting the pulse width of a PWM signal in the PWM circuit. According to the detected pulse width, a digital delay less than the pulse width of the PWM signal is selected from among a plurality of available digital delays. Further, an over-current condition in the PWM power stage is detected. The detected over-current signal is filtered by means of the selected digital delay and an over-current detection result is output.